AAAAAA

   
Results: 1-9 |
Results: 9
TRANSFERABILITY TO CLINICAL-PRACTICE OF THE RESULTS OF CONTROLLED CLINICAL-TRIALS - THE CASE OF ANTIEMETIC PROPHYLACTIC TREATMENT FOR CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
Authors: DELFAVERO A ROILA F DEANGELIS V TONATO M BALLATORI E TUMOLO S MENEGHETTI L NEGRI D DELLAGASPERA S PRESOT C MURAN G LUCENTI A CICCARESE G PALLADINO MA PORROZZI S SABBATINI R DEPENNI R FEDERICO M SILINGARDI V SANSONI E MALTONI M MILANDRI C AMADORI D SABBIONI R NORTILLI R CETTO GL DOGLIOTTI L BUNIVA T GORZEGNO G LOPEZ M AMODIO A CONTI F FOGGI CM GIGLIO A DESIO L MANENTE P BERNARDO G STRADA MR VILLANI G GALLO L MERLINI L CAROTI C MAZZOTTA S FORCIGNANO R QUARTA G PACILIO C IODICE G ROSATI G MALACARNE P DONATI D MACCAFERRI R COMELLA G CASARETTI R CARRECA I RAUSA L FOSSER V SCHIAVON S GIOFFRE FM VENUTI A AMUNNI G VILLANUCCI A CONTU A PAZZOLA A PALMIOTTI G GAROFOLO G EPIFANI C GIORDANO M ANTIMI M MINELLI M DEVITA F DIGRAZIA M CRUCIANI G MONTANARI L MARCHEI P AMICI S ALESSANDRONI P CECCOLINI M CATTANEO MT ORLANDINI B AGOSTARA B MARZI M DIONISI MS DICOSTANZO F TROCCOLI L
Citation: A. Delfavero et al., TRANSFERABILITY TO CLINICAL-PRACTICE OF THE RESULTS OF CONTROLLED CLINICAL-TRIALS - THE CASE OF ANTIEMETIC PROPHYLACTIC TREATMENT FOR CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, Annals of oncology, 9(7), 1998, pp. 759-765
CISPLATIN, EPIRUBICIN, AND LONIDAMINE COMBINATION REGIMEN AS FIRST-LINE CHEMOTHERAPY FOR METASTATIC BREAST-CANCER - A PILOT-STUDY
Authors: DOGLIOTTI L DANESE S BERRUTI A ZOLA P BUNIVA T BOTTINI A RICHIARDI G MORO G FARRIS A BAU MG PORCILE G
Citation: L. Dogliotti et al., CISPLATIN, EPIRUBICIN, AND LONIDAMINE COMBINATION REGIMEN AS FIRST-LINE CHEMOTHERAPY FOR METASTATIC BREAST-CANCER - A PILOT-STUDY, Cancer chemotherapy and pharmacology, 41(4), 1998, pp. 333-338
RANDOMIZED COMPARISON OF GOSERELIN ACETATE VERSUS MITOMYCIN-C PLUS GOSERELIN ACETATE IN PREVIOUSLY UNTREATED PROSTATE-CANCER PATIENTS WITH BONE METASTASES
Authors: FONTANA D BERTETTO O FASOLIS G BERRUTI A TARABUZZI R PAGANI G BUNIVA T ZOLFANELLI R PALLOTTI S FREZZOTTI L BUMMA C ROSSETTI SR DOGLIOTTI L
Citation: D. Fontana et al., RANDOMIZED COMPARISON OF GOSERELIN ACETATE VERSUS MITOMYCIN-C PLUS GOSERELIN ACETATE IN PREVIOUSLY UNTREATED PROSTATE-CANCER PATIENTS WITH BONE METASTASES, Tumori, 84(1), 1998, pp. 39-44
PROGNOSTIC FACTORS IN METASTATIC BREAST-CANCER PATIENTS OBTAINING OBJECTIVE RESPONSE OR DISEASE STABILIZATION AFTER FIRST-LINE CHEMOTHERAPYWITH EPIRUBICIN - EVIDENCE FOR A POSITIVE EFFECT OF MAINTENANCE HORMONAL-THERAPY ON OVERALL SURVIVAL
Authors: BERRUTI A ZOLA P BUNIVA T BAU MG FARRIS A SAROBBA MG BOTTINI A TAMPELLINI M DURANDO A DESTEFANIS M MONZEGLIO C MORO G SUSSIO M PERRONI D DOGLIOTTI L
Citation: A. Berruti et al., PROGNOSTIC FACTORS IN METASTATIC BREAST-CANCER PATIENTS OBTAINING OBJECTIVE RESPONSE OR DISEASE STABILIZATION AFTER FIRST-LINE CHEMOTHERAPYWITH EPIRUBICIN - EVIDENCE FOR A POSITIVE EFFECT OF MAINTENANCE HORMONAL-THERAPY ON OVERALL SURVIVAL, Anticancer research, 17(4A), 1997, pp. 2763-2768
RELATIONSHIP BETWEEN CA-15-3 SERUM LEVELS AND DISEASE EXTENT IN PREDICTING OVERALL SURVIVAL OF BREAST-CANCER PATIENTS WITH NEWLY-DIAGNOSED METASTATIC DISEASE
Authors: TAMPELLINI M BERRUTI A GERBINO A BUNIVA T TORTA M GORZEGNO G FAGGIUOLO R CANNONE R FARRIS A DESTEFANIS M MORO G DELTETTO F DOGLIOTTI L
Citation: M. Tampellini et al., RELATIONSHIP BETWEEN CA-15-3 SERUM LEVELS AND DISEASE EXTENT IN PREDICTING OVERALL SURVIVAL OF BREAST-CANCER PATIENTS WITH NEWLY-DIAGNOSED METASTATIC DISEASE, British Journal of Cancer, 75(5), 1997, pp. 698-702
LONIDAMINE SIGNIFICANTLY INCREASES THE ACTIVITY OF EPIRUBICIN IN PATIENTS WITH ADVANCED BREAST-CANCER - RESULTS FROM A MULTICENTER PROSPECTIVE RANDOMIZED TRIAL
Authors: DOGLIOTTI L BERRUTI A BUNIVA T ZOLA P BAU MG FARRIS A SAROBBA MG BOTTINI A ALQUATI P DELTETTO F GOSSO P MONZEGLIO C MORO G SUSSIO M PERRONI D
Citation: L. Dogliotti et al., LONIDAMINE SIGNIFICANTLY INCREASES THE ACTIVITY OF EPIRUBICIN IN PATIENTS WITH ADVANCED BREAST-CANCER - RESULTS FROM A MULTICENTER PROSPECTIVE RANDOMIZED TRIAL, Journal of clinical oncology, 14(4), 1996, pp. 1165-1172
PROGNOSTIC VALUE OF CA-15-3 IN ADVANCED BREAST-CANCER (BC) PATIENTS -RELATIONSHIP WITH THE DISEASE EXTENT (DE)
Authors: TAMPELLINI M BERRUTI A GERBINO A BUNIVA T TORTA M FAGGIUOLO R GORZEGNO G DOGLIOTTI L
Citation: M. Tampellini et al., PROGNOSTIC VALUE OF CA-15-3 IN ADVANCED BREAST-CANCER (BC) PATIENTS -RELATIONSHIP WITH THE DISEASE EXTENT (DE), European journal of cancer, 31A, 1995, pp. 681-681
A RANDOMIZED COMPARISON OF HIGH-DOSE EPIRUBICIN VERSUS HIGH-DOSE EPIRUBICIN PLUS LONIDAMINE IN ADVANCED BREAST-CANCER PATIENTS - FIRST RESULTS FROM A COOPERATIVE GROUP-STUDY
Authors: DOGLIOTTI L BERRUTI A BUNIVA T ZOLA P BAU MG FARRIS A SAROBBA MG BOTTINI A ALQUATI P DELTETTO F GOSSO P MONZEGLIO C MORO G SUSSIO M PERRONI D
Citation: L. Dogliotti et al., A RANDOMIZED COMPARISON OF HIGH-DOSE EPIRUBICIN VERSUS HIGH-DOSE EPIRUBICIN PLUS LONIDAMINE IN ADVANCED BREAST-CANCER PATIENTS - FIRST RESULTS FROM A COOPERATIVE GROUP-STUDY, International journal of oncology, 4, 1994, pp. 747-752
PROGNOSTIC VALUE IN PREDICTING OVERALL SURVIVAL OF 2 MUCINOUS MARKERS- CA-15-3 AND CA-125 IN BREAST-CANCER PATIENTS AT FIRST RELAPSE OF DISEASE
Authors: BERRUTI A TAMPELLINI M TORTA M BUNIVA T GORZEGNO G DOGLIOTTI L
Citation: A. Berruti et al., PROGNOSTIC VALUE IN PREDICTING OVERALL SURVIVAL OF 2 MUCINOUS MARKERS- CA-15-3 AND CA-125 IN BREAST-CANCER PATIENTS AT FIRST RELAPSE OF DISEASE, European journal of cancer, 30A(14), 1994, pp. 2082-2084
Risultati: 1-9 |